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S U M M A R Y
Objectives: We studied the clinical characteristics, in-hospital mortality, and long-term prognosis of
patients with culture-negative endocarditis.
Methods: In total, 221 episodes of deﬁnite endocarditis were studied (2004–2009). We compared the
clinical, laboratory, and echocardiography characteristics and the survival rates of patients with culture-
negative and culture-positive endocarditis. Survival after hospital discharge was evaluated using the
Kaplan–Meier method and coefﬁcient of mortality comparisons.
Results: Culture-negative endocarditis occurred in 51/221 (23.1%) episodes. Compared with the culture-
positive endocarditis patients, the time elapsed between admission and initiation of antibiotic therapy
was longer in patients with culture-negative endocarditis (p < 0.001), and these patients also had lower
C-reactive protein levels at admission (p < 0.001). In-hospital mortality rates were not different between
culture-negative and culture-positive patients. After hospital discharge, there was also no signiﬁcant
difference between groups in survival curves (p = 0.471). Severe sepsis (adjusted prevalence ratio 3.32,
p = 0.010) and diabetes mellitus (adjusted prevalence ratio 2.32, p = 0.009) were independently
associated with in-hospital death in culture-negative patients.
Conclusions: Culture-negative endocarditis patients presented with lower levels of C-reactive protein at
admission and required more time for initiation of antibiotic therapy, although there was no difference
in in-hospital mortality or long-term survival between culture-negative and culture-positive
endocarditis patients. Diabetes mellitus and severe sepsis were associated with in-hospital death in
patients with culture-negative endocarditis.
 2014 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/3.0/).
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Culture-negative endocarditis remains a diagnostic and thera-
peutic challenge. Although new techniques, such as those
involving molecular biology, are highly sensitive for the identiﬁ-
cation of causative microorganisms when applied to cardiac valve
in surgically treated patients, their sensitivity is low when
peripheral blood is analyzed.1–3
The clinical characteristics and prognosis associated with this
conditionmayvaryaccordingtodifferentepidemiologicalandclinical
factors. Empirical antimicrobial treatment is based on epidemiologi-
cal data and previous exposure to microorganisms,4–6 although* Corresponding author. Tel.: +55 11 26615349; fax: +55 11 26615538.
E-mail address: rinaldo_focaccia@uol.com.br (R.F. Siciliano).
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1201-9712/ 2014 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).unusual or fastidious microorganisms can also cause endocarditis,
especially in cases of community-acquired endocarditis.7,8
We hypothesized that culture-negative endocarditis cases may
present different clinical characteristics and prognoses compared
to cases with an identiﬁed microbial pathogen. Thus, we compared
the clinical characteristics, in-hospital mortality, and long-term
prognoses between endocarditis patients with and without a
causative microorganism identiﬁed in blood culture.
2. Methods
2.1. Study setting, clinical setting, and patients
Using an inception cohort, we studied 221 cases of infective
endocarditis admitted to a 514-bed tertiary cardiology hospitalciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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included in this inception cohort consecutively at diagnosis of
endocarditis, which was considered the time at which active
parenteral antibiotic treatment was started. The inclusion criteria
were age >18 years and ‘deﬁnite’ endocarditis (according to the
modiﬁed Duke criteria9) involving a native or prosthetic valve. The
exclusion criteria were as follows: (1) patients with prosthetic
valve endocarditis in the ﬁrst postoperative year, (2) hemodialysis
patients, and (3) nosocomial endocarditis patients (i.e., those with
symptoms attributed to endocarditis that started 72 h after
hospital admission or within 6 months of a hospital-associated
invasive procedure10,11).
Our hospital follows international recommendations for
speciﬁc antibiotic therapy for endocarditis.12 Empirical antibiotic
treatment for culture-negative endocarditis is the association of
intravenous (IV) penicillin G (24 million units/day in divided doses
every 4 h) plus IV oxacillin (12 g/day in divided doses every 4 h) 
IV gentamicin (1 mg/kg every 8 h). The patients ranged in age from 18
to 90 years (mean 53 years, standard deviation 18.4 years); 144
(65.2%) were male and 77 (34.8%) were female. Native valve
endocarditis occurred in 114 patients and valvular heart disease
occurred in 79 patients (chronic rheumatic heart disease occurred in
29, mitral valve prolapse in 19, and congenital heart disease in 22).
Nine patients presented evidence of previous endocarditis. Prosthetic
valve endocarditis occurred in 107 patients. Left-sided endocarditis
occurred in 209 patients (mitral or aortic), and right-sided
endocarditis occurred in 12 patients.
2.2. Diagnostic work-up
After the clinical examination, three sets of blood cultures
(aerobic/anaerobic) containing 5–10 ml of blood in each sample
were drawn by independent punctures at least 30 min apart using
an aseptic technique. The blood samples were incubated for 5 days.
Automated BACTEC (BD Diagnostics, Sparks, MA, USA) and VITEK 2
(bioMe´rieux, Marcy l’Etoile, France) systems were used for the
identiﬁcation of microorganisms and susceptibility testing. In the
event that a microorganism was not identiﬁed in the blood culture,
indirect immunoﬂuorescence assays were performed for Bartonella
henselae, Bartonella quintana, and Coxiella burnetii. Sera that
showed ﬂuorescence at a dilution 1:800 for B. henselae, B.
quintana, or C. burnetii anti-phase I were considered positive.13,14
When available, surgically removed and formalin-ﬁxed, paraf-
ﬁn-embedded 5-mm thick valve tissue sections were submitted to
B. henselae, B. quintana, and C. burnetii immunohistochemistry.
2.3. Variables studied
The following variables were studied: (1) demographic data
(sex and age); (2) predisposing diseases (valvular heart disease,
cyanotic congenital heart disease, prosthetic cardiac valve, and
previous endocarditis); (3) comorbidities (diabetes mellitus,
arterial hypertension, creatinine clearance <30 ml/min, AIDS,
and patients undergoing chemotherapy); (4) antimicrobial ad-
ministration prior to blood draw (these data were obtained
prospectively by interview with culture-negative patients); (5)
endocarditis characteristics at admission (type and duration of
symptoms, hospitalization time until initiation of antibiotic
therapy for endocarditis, location of endocarditis (right or left
side), and native or prosthetic valve); (6) C-reactive protein level
on admission, vegetation on echocardiography, left ventricular
ejection fraction, and valve regurgitation; (7) endocarditis
treatment (valve surgery and the use of aminoglycoside combined
antibiotic treatment); (8) complications (severe sepsis at admis-
sion (according to the criteria of Bone et al.15), the occurrence of
renal failure during hospital stay (Acute Kidney Injury Networkcriteria16), atrioventricular block, myocardial abscess, cardiac
ﬁstula, glomerulonephritis, and embolization); (9) follow-up (all
patients were contacted by telephone at the end of follow-up –
February 1, 2013); (10) relapse (deﬁned as a new episode of
endocarditis within 6 months after the end of treatment, with a
negative blood culture or culture with the same microorganism
identiﬁed previously17); in these cases, only the ﬁrst episode was
included.
2.4. Statistical analysis
Qualitative variables were compared between study groups
using the Chi-square test or Fisher’s exact test. Univariate analysis
was performed to establish the prevalence ratio between clinical
and laboratory variables as well as in-hospital mortality, with the
corresponding 95% conﬁdence intervals (95% CI). All variables with
p < 0.20 in the univariate analysis were tested in the multivariate
Cox regression model with robust variance for transversal analysis
(stepwise forward). After hospital discharge, the probability of
survival was evaluated using the Kaplan–Meier method, and
survival was compared between the negative and positive culture
groups using the log-rank test. These analyses were performed
using Stata 11.0 (StataCorp LP, College Station, TX, USA).
2.5. Ethical aspects
This study was approved by the ethics committee on human
research of the Heart Institute (InCor), University of Sao Paulo
Medical School.
3. Results
3.1. Clinical characteristics
We identiﬁed the causative microorganisms in 170 episodes of
endocarditis, whereas 51 (23.1%) blood cultures were negative. Of
the culture-negative patients, 24 (47.1%) received antibiotic
therapy prior to the blood draw, including ﬁve cases (20.8%) at
our institution, 18 (75%) during a previous hospitalization, and one
(4.2%) who used self-medication.
Comorbidities were diagnosed in 152 (68.3%) patients. These
conditions included diabetes mellitus in 25 patients (11.3%),
hypertension in 91 patients (41.2%), heart failure in 78 patients
(35.3%), chronic renal failure in 15 patients (6.8%), and chronic
obstructive pulmonary disease in four patients (1.8%).
The following microorganisms were identiﬁed: viridans type
streptococci in 81 (47.6%) patients, Enterococcus spp in 20 patients
(11.7%), Streptococcus bovis in 17 patients (10%), Staphylococcus
aureus in 14 patients (8.2%), other streptococci in 11 patients
(6.5%), HACEK microorganisms in 13 patients (7.7%), coagulase-
negative staphylococci in six patients (3.5%), and Candida spp,
Bacteroides fragilis, Citrobacter diversus, Salmonella spp, Serratia
marcescens, Flavobacterium spp, and Corynebacterium spp in one
patient each.
Patients with negative blood cultures presented Bartonella spp
infection (10 patients) or C. burnetii infection (four patients).
Immunohistochemical valvular pathology conﬁrmed these ﬁnd-
ings in nine patients who were submitted to surgical treatment.
3.2. Culture-negative endocarditis vs. culture-positive endocarditis
Table 1 describes the clinical characteristics of patients with
culture-negative and culture-positive endocarditis. Interestingly,
using the median value to categorize continuous variables, the
levels of C-reactive protein were lower (median 58 mg/l vs. median
106 mg/l, p < 0.001) and the time elapsed between admission and
Table 1
Clinical and laboratory characteristics of community-acquired endocarditis according to the identiﬁcation of causative microorganisms in culture
Factor Total
number
Microorganisms on culture p-Valuea
Identiﬁed, n (%) Not identiﬁed, n (%)
Male gender 221 108 (63.5) 36 (70.5) 0.353
Age 60 years 221 74 (43.5) 16 (31.4) 0.121
Valvular heart disease 221 144 (84.7) 40 (78.4) 0.293
Prosthetic valve endocarditis 221 85 (50.0) 22 (43.1) 0.427
Comorbidities 221 118 (69.4) 34 (66.7) 0.711
Duration of symptoms 30 days 220 75 (44.4) 28 (54.9) 0.187
Fever 220 153 (90.5) 44 (86.3) 0.384
Glomerulonephritis 183 34 (25.0) 1 (21.3) 0.607
C-reactive protein 80 mg/l 151 78 (68.4) 14 (37.8) 0.001
Severe sepsis 221 61 (35.9) 19 (37.3) 0.858
Time between admission and initiation of
antibiotic therapy for IE >2 days
221 27 (15.9) 16 (31.4) 0.014
Right side IE 219 9 (5.4) 3 (5.9) >0.999b
Left side IE 221 161 (94.7) 46 (90.2) >0.999b
Vegetation on echocardiography 219 129 (76.8) 42 (82.3) 0.400
Renal failure 221 85 (50.0) 29 (53.9) 0.390
Atrioventricular block 221 28 (16.5) 4 (7.8) 0.125
Myocardial abscess 221 44 (25.9) 15 (29.4) 0.617
Cardiac ﬁstula 221 4 (2.4) 4 (7.8) 0.085b
Embolization 221 58 (34.1) 18 (35.3) 0.877
Aminoglycoside-containing therapy 221 133 (78.3) 40 (78.8) 0.976
Surgical treatment 221 92 (54.1) 24 (47.1) 0.376
In-hospital death 221 33.4% 31.4% 0.774
IE, infective endocarditis.
a Chi-square test.
b Fisher’s exact test.
R.F. Siciliano et al. / International Journal of Infectious Diseases 25 (2014) 191–195 193initiationofantibiotictherapywaslonger(median2daysvs.median
0 days, p < 0.001) in patients with culture-negative endocarditis
compared with culture-positive endocarditis patients.
One hundred and sixteen patients (52.4%) were submitted to
surgical treatment. The global in-hospital mortality rate was 33%
(95% CI 26.9–39.7), and this rate was not different (p = 0.774)
between culture-negative endocarditis (31.4%, 95% CI 19.1–46.0)
and culture-positive endocarditis patients (33.4%, 95% CI 26.5–
41.2). Four patients experienced relapse, including two in the
culture-negative group and two in the culture-positive group.
The mean follow-up time of patients after hospital discharge
was 6 years (standard deviation 1.6 years). Five years after
discharge, 85.3% of patients remained alive. No information could be
obtained concerning the outcome in six patients (loss to follow-up
4.1%). The comparison of survival time after hospital discharge was
also not signiﬁcantly different (p = 0.471) between the positive and
negative culture groups, as demonstrated by the Kaplan–Meier curves
(Figure 1).Figure 1. Kaplan–Meier survival curve for endocarditis according to culture results
(p = 0.471).3.3. In-hospital prognosis of patients with culture-negative
endocarditis
Survival data for the negative blood culture patients are
presented in Table 2. Multivariate Cox regression revealed that
only severe sepsis (adjusted prevalence ratio 3.32, 95% CI 1.34–
8.23; p = 0.010) and diabetes mellitus (adjusted prevalence ratio
2.32, 95% CI 1.23–4.37; p = 0.009) were associated with in-hospital
death (Table 2).
4. Discussion
In our study, the frequency of culture-negative endocarditis
was 22.5% (95% CI 17.2–28.5). Previous endocarditis case series
have reported frequencies of negative cultures ranging from 12% to
60%.18–23 Failure to culture the microorganism responsible for
endocarditis may be the result of antimicrobial treatment prior to
blood culture or infection with highly fastidious bacteria or with
nonbacterial pathogens.8 In this study, 47% of patients with
culture-negative endocarditis were treated with antimicrobial
drugs prior to blood draw, and the majority of these cases (75%)
received the ﬁrst antibiotic dose prior to hospital admission. As a
referral hospital, most patients at our hospital had already received
antibiotics at the time of admission.
We did not observe a lower frequency of fever in patients with
negative blood cultures, as reported previously.24–26 However, the
lower values of C-reactive protein in the culture-negative endocar-
ditis patients may be indicative of a less intense systemic
inﬂammatory response secondary to fastidious infections. Our study
found no differences between the groups (with positive and negative
blood cultures) regarding cardiac or systemic complications of
endocarditis. However, previous authors have observed a lower
frequency of complications such as embolism27 and perivalvular
abscess24,25,28 among patients with culture-negative endocarditis.
We hypothesized that delays in identifying the causative
organism and consequently administering the appropriate therapy
could result in poor clinical outcomes. However, we found no
Table 2
Distribution of clinical and laboratory characteristics of culture-negative endocarditis patients according to in-hospital mortality
Factor Survivors
(n = 35)
Non-survivors
(n = 16)
Prevalence ratio 95% CI p-Value
Male gender 25 (71.4%) 11 (68.7%) 0.92 0.38–2.20 0.846
Age 60 years 7 (20%) 9 (56.2%) 2.81 1.27–6.25 0.011
Valvular heart disease 26 (74.2%) 14 (87.5%) 1.93 0.51–7.32 0.337
Hypertension 12 (34.2%) 9 (42.9%) 1.84 0.81–4.18 0.148
Diabetes mellitus 1 (2.8%) 4 (80.0%) 3.07 1.58–5.94 0.001
Duration of symptoms 30 days 20 (57.1%) 8 (28.6%) 0.82 0.36–1.86 0.637
Fever 32 (91.4%) 12 (27.3%) 0.48 0.21–1.07 0.074
C-reactive protein 80 mg/l (n = 37) 10 (29.4%) 4 (28.6%) 0.82 0.30–2.26 0.704
Severe sepsis 8 (22.8%) 11 (57.9%) 3.71 1.51–9.12 0.004
Blood cultures collected without the prior use of antibiotics 19 (54.2%) 5 (20.8%) 0.51 0.21–1.27 0.149
Time between admission and diagnosis of IE >2 days 17 (48.5%) 10 (37.0%) 1.48 0.63–3.49 0.369
Right side IE 2 (3.6%) 1 (33.3%) 1.07 0.20–5.67 0.940
Left side IE 31 (60.7%) 15 (32.6%) 1.63 0.26–10.06 0.598
Bartonella spp infection 6 (17.1%) 4 (40.0%) 1.37 0.55–3.38 0.499
Coxiella burnetii infection 3 (8.5%) 1 (25.0%) 0.78 0.13–4.58 0.786
LVEF 45% (n = 50) 7 (20.5%) 5 (41.7%) 1.52 0.81 – 2.60 0.380
Moderate or severe valvular regurgitation 27 (77.1%) 11 (29.0%) 0.75 0.32–1.77 0.516
Aminoglycoside-containing therapy 28 (0.8%) 12 (30.0%) 0.83 0.33–2.08 0.683
Surgical treatment 20 (57.1%) 7 (25.9%) 0.69 0.30–1.58 0.383
Atrioventricular block 3 (8.5%) 1 (25.0%) 0.78 0.13–4.58 0.786
Myocardial abscess 9 (25.7%) 6 (40.0%) 1.44 0.63–3.27 0.384
Cardiac ﬁstula 4 (11.4%) 2 (50.0%) 1.45 0.54–3.86 0.457
Embolization 9 (25.7%) 9 (50.0%) 2.36 1.05–5.31 0.038
CI, conﬁdence interval; IE, infective endocarditis; LVEF, left ventricular ejection fraction.
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according to blood culture positivity, although the initiation of
antibiotic therapy in the culture-negative endocarditis group
required additional time. In the last 20 years, seven studies18,24–29
have compared in-hospital mortality in patients with positive and
negative endocarditis cultures, and only one study28 found
differences between these groups, with a lower mortality rate
observed in culture-negative endocarditis patients. However, in
that study,28 75% of cases with culture-negative endocarditis were
classiﬁed as ‘possible’ and may therefore not represent true
endocarditis cases, which could explain the improved survival
observed for this group. We restricted our analysis to patients with
community-acquired endocarditis that was classiﬁed as ‘deﬁnite’
according to the modiﬁed Duke criteria.9
Long-term survival was analyzed in a previous study29 in
patients with surgically treated endocarditis, and the results
showed lower late survival rates in cases of culture-negative
endocarditis.
We observed that antibiotic administration prior to blood
culture collection did not affect hospital mortality among culture-
negative endocarditis patients, as reported in other studies.18,26,30
However, the presence of diabetes mellitus and the occurrence of
severe sepsis on admission among culture-negative endocarditis
patients were independently associated with in-hospital death.
These two clinical conditions were described previously as factors
associated with a poor prognosis in endocarditis patients, but few
studies have examined these risk factors among culture-negative
endocarditis patients.31–33 In a univariate analysis, one previous
study18 found an association between hospital mortality and the
following variables in patients with culture-negative endocarditis:
deﬁnite endocarditis, the presence of heart failure, kidney failure,
and embolism. In addition, Werner et al.28 observed signiﬁcantly
higher hospital mortality rates in patients with culture-negative
endocarditis who did not receive treatment with an aminoglyco-
side as part of empirical antibiotic therapy. In our series, 21% of
culture-negative endocarditis patients did not receive an amino-
glycoside as empirical treatment, and there was no difference in
hospital mortality between culture-positive and culture-negative
endocarditis patients regarding the use of aminoglycoside-con-
taining therapy.In conclusion, culture-negative endocarditis patients demon-
strated similar clinical characteristics at admission, with the
exception of lower C-reactive protein levels and a slightly longer
time required for initiation of antibiotic therapy. In-hospital
mortality and long-term survival were also similar between
culture-negative and culture-positive endocarditis patients. Dia-
betes mellitus and severe sepsis were associated with in-hospital
death in patients with culture-negative endocarditis.
Conﬂict of interest: All authors declare no ﬁnancial or personal
relationships with other people or organizations that could
inappropriately inﬂuence (bias) their work.
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